A phase I study of the safety, tolerability and antitumor activity of escalating doses of combretastatin A4 phosphate (CA4P) given in combination with bevacizumab to subjects with advanced solid tumors

A phase I study of the safety, tolerability and antitumor activity of escalating doses of combretastatin A4 phosphate (CA4P) given in combination with bevacizumab to subjects with advanced solid tumors

書目詳細資料
Main Authors:	Nathan, P, Judson, I, Padhani, A, Harris, A, Sinha, R, Jane, B, Smythe, J, Fisher, N, Taylor, J, Collins, D, Connors, H, Gordon, R
格式:	Journal article
出版:	2007

相似書籍

A phase I study of combretastatin A4 phosphate (CA4P) and bevacizumab in subjects with advanced solid tumors
由: Nathan, P, et al.
出版: (2008)

Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer.
由: Nathan, P, et al.
出版: (2012)

Vascular effects dominate solid tumor response to treatment with combretastatin A-4-phosphate
由: Jane Lunt, S, et al.
出版: (2011)

The vascular response of tumor and normal tissues in the rat to the vascular targeting agent, combretastatin A-4-phosphate, at clinically relevant doses.
由: Prise, V, et al.
出版: (2002)

Vascular effects dominate solid tumor response to treatment with combretastatin A-4-phosphate.
由: Lunt, S, et al.
出版: (2011)

A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer.
由: Rustin, G, et al.
出版: (2010)

Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results.
由: Rustin, G, et al.
出版: (2003)

Nitric oxide synthase inhibition enhances the tumor vascular-damaging effects of combretastatin a-4 3-o-phosphate at clinically relevant doses.
由: Tozer, G, et al.
出版: (2009)

The vascular targeting agent combretastatin A-4-phosphate induces neutrophil recruitment to endothelial cells in vitro.
由: Brooks, A, et al.
出版: (2003)

Dichloroacetate reverses the hypoxic adaptation to bevacizumab and enhances its antitumor effects in mouse xenografts
由: Kumar, K, et al.
出版: (2013)

Dichloroacetate reverses the hypoxic adaptation to bevacizumab and enhances its antitumor effects in mouse xenografts.
由: Kumar, K, et al.
出版: (2013)

Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer.
由: Zweifel, M, et al.
出版: (2011)

Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo.
由: Galbraith, S, et al.
出版: (2001)

Combretastatin A-4 phosphate (CA4P) carboplatin and paclitaxel in patients with platinum-resistant ovarian cancer: Final phase II trial results
由: Zweifel, M, et al.
出版: (2009)

Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability.
由: Tozer, G, et al.
出版: (2001)

A phase I trial of radioimmunotherapy with 131I-A5B7 anti-CEA antibody in combination with combretastatin-A4-phosphate in advanced gastrointestinal carcinomas.
由: Meyer, T, et al.
出版: (2009)

Personalized dose escalation in anal cancer
由: Robinson, M, et al.
出版: (2016)

Synthesis and biological properties of bioreductively targeted nitrothienyl prodrugs of combretastatin A-4.
由: Thomson, P, et al.
出版: (2006)

Dose escalation of 5ASA: does it work?
由: Travis, S
出版: (2005)

Improved Outcomes With Dose Escalated Hypofractionated Radiotherapy for Prostate Cancer
由: Mackenzie, J, et al.
出版: (2011)

Treatment planning of dose escalation for anal cancer in the PLATO trial
由: Abbott, N, et al.
出版: (2017)

Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours.
由: Dean, E, et al.
出版: (2012)

Bevacizumab--current status and future directions.
由: Midgley, R, et al.
出版: (2005)

Is nevirapine dose-escalation appropriate in young, African, HIV-infected children?
由: Fillekes, Q, et al.
出版: (2013)

Normal tissue doses during isotoxically dose escalated lung radiation therapy using MR-linacs
由: Bendall, L, et al.
出版: (2018)

Influence of dose calculation algorithms on isotoxic dose-escalation of non-small cell lung cancer radiotherapy.
由: Panettieri, V, et al.
出版: (2010)

Effect of Modified Vaccinia Ankara–5T4 and Low-Dose Cyclophosphamide on Antitumor Immunity in Metastatic Colorectal Cancer: A Randomized Clinical Trial
由: Scurr, M, et al.
出版: (2017)

A phase 1 dose-finding and pharmacodynamic study of rapamycin in combination with bevacizumab in patients with unresectable hepatocellular carcinoma
由: Choo, S. P., et al.
出版: (2013)

Intensity-modulated radiotherapy allows escalation of the radiation dose to the pelvic lymph nodes in patients with locally advanced prostate cancer: preliminary results of a phase I dose escalation study.
由: Guerrero Urbano, T, et al.
出版: (2010)

The tolerability of single low dose primaquine in glucose-6-phosphate deficient and normal falciparum-infected Cambodians
由: Dysoley, L, et al.
出版: (2019)

Clinical and dosimetric factors impacting radiation pneumonitis in isotoxically dose-escalated NSCLC
由: Vivekanandan, S, et al.
出版: (2017)

Assessing early therapeutic response to bevacizumab in primary breast cancer using magnetic resonance imaging and gene expression profiles.
由: Mehta, S, et al.
出版: (2011)

Bevacizumab and type 1 idiopathic macular telangiectasia
由: Koay, C.L., et al.
出版: (2011)

Biomarkers to predict the clinical efficacy of bevacizumab in cancer.
由: Jubb, A, et al.
出版: (2010)

Enhanced fluorescence detection of cis-combretastatins by post-column photolysis.
由: Stratford, MR
出版: (2008)

Phase I/II trial of bevacizumab and radiotherapy for locally advanced inoperable colorectal cancer: vasculature-independent radiosensitizing effect of bevacizumab.
由: Koukourakis, M, et al.
出版: (2009)

Antitumor and antioxidant effects of Clinacanthus nutans Lindau in 4T1 tumor-bearing mice
由: Nik Abd Rahman, Nik Mohd Afizan, et al.
出版: (2019)

Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects.
由: Ruocco, MG, et al.
出版: (2012)

On escalation and deterrence
由: Pool, Ithiel de Sola, 1917-1984
出版: (2014)

Dose escalation for non-small cell lung cancer: analysis and modelling of published literature.
由: Partridge, M, et al.
出版: (2011)